ArticleNutrition research and practice2026
Modulatory effects of
Article in Nutrition research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesThe dysregulation of the dopamine (DA) system is a key factor in neurodevelopmental and neurodegenerative disorders, including attention-deficit hyperactivity disorder (ADHD), Parkinson's disease, and schizophrenia. The habenula is a crucial regulator of DA neurotransmission and has been implicated in the pathophysiology of ADHD. MATERIALS/
methodsSH-SY5Y cells were treated with HF extracts at concentrations of 0.1, 1, and 10 μg/mL for 24 h, followed by immunostaining to evaluate DA-related protein expression. Male Sprague-Dawley rats were provided bilateral habenular injections of ibotenic acid (0.15 μL of 10 μg/μL in artificial cerebrospinal fluid) on postnatal day (PND) 7. HF extract was administered orally once daily from PND 21-28. Subsequently, behavioral assessments were conducted during the juvenile period (PND 28-35).
resultsHF treatment selectively downregulated dopamine receptor D (DRD)-2 and DRD5, whereas the levels of DRD1, DRD3, and DRD4 remained unchanged in SH-SY5Y cells. Behavioral analyses revealed that HF administration significantly ameliorated NHL-induced hyperactivity, attentional deficits, and impulsive behaviors in juvenile rats.
conclusionThese findings suggest that HF functions as a DRD2/DRD5 modulator, contributing to DA system regulation and potentially mediating anti-ADHD effects. Further studies are required to elucidate the mechanisms underlying the neuromodulatory effects of HF and its therapeutic potential for DA-related neuropsychiatric disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.